Ehsan Moazen-Zadeh
Overview
Explore the profile of Ehsan Moazen-Zadeh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
338
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moazen-Zadeh E, Chisholm A, Bachi K, Hurd Y
Cannabis Cannabinoid Res
. 2023 Aug;
9(4):939-966.
PMID: 37643301
In this review, we provide an updated assessment of available evidence on the pharmacokinetics (PK) of CBD and explore the impact of different factors on PK outcomes. This systematic review...
2.
Moazen-Zadeh E, Chisholm A, Bachi K, Hurd Y
medRxiv
. 2023 Feb;
PMID: 36778355
Background: In this review, we provide an updated assessment of available evidence on the pharmacokinetics (PK) of cannabidiol (CBD) and explore the impact of different factors on PK outcomes. Materials...
3.
Nikoo M, Kianpoor K, Nikoo N, Javidanbardan S, Kazemi A, Choi F, et al.
Addiction
. 2022 Aug;
118(2):284-294.
PMID: 35971297
Aim: To test if opium tincture (OT) was non-inferior to methadone in retaining participants in opioid agonist treatment (OAT). Design: A Phase III, multi-centre, parallel-group, non-inferiority, double-blind randomized controlled trial...
4.
Moazen-Zadeh E, Ziafat K, Yazdani K, Kamel M, Wong J, Modabbernia A, et al.
Am J Drug Alcohol Abuse
. 2021 Mar;
47(3):280-304.
PMID: 33780647
: There is a knowledge gap in systematic reviews on the impact of opioid agonist treatments on mental health.: We compared mental health outcomes between different opioid agonist treatments and...
5.
Shams F, Wong J, Nikoo M, Outadi A, Moazen-Zadeh E, Kamel M, et al.
J Med Internet Res
. 2021 Jan;
23(1):e20557.
PMID: 33475520
Background: There is a growing body of evidence regarding eHealth interventions that target substance use disorders. Development and funding decisions in this area have been challenging, due to a lack...
6.
Moazen-Zadeh E, Galynker I
Curr Neuropharmacol
. 2020 Oct;
19(6):733-735.
PMID: 33059579
Cannabidiol (CBD) is gaining considerable attention in the research community with promising results in a variety of neuropsychiatric conditions. In particular, there are replicated findings for the therapeutic effects of...
7.
Saraf G, Moazen-Zadeh E, Pinto J, Ziafat K, Torres I, Kesavan M, et al.
Lancet Psychiatry
. 2020 Aug;
8(1):64-75.
PMID: 32857954
Early intervention approaches are built on the premise of preventing disability, burden, and cognitive sequelae caused by bipolar disorder. The objective of this systematic review was to characterise the effectiveness...
8.
Snowdon J, Saberi S, Moazen-Zadeh E
East Mediterr Health J
. 2020 Jul;
26(6):748-754.
PMID: 32621512
Background: When planning interventions aimed at preventing suicide, it is important to consider how socioeconomic and cultural factors may affect suicide rates. There has been variability in the accuracy of...
9.
Krausz M, Wong J, Moazen-Zadeh E, Jang K
Can J Psychiatry
. 2020 Mar;
65(6):377-380.
PMID: 32174152
No abstract available.
10.
Moazen-Zadeh E, Bayanati S, Ziafat K, Rezaei F, Mesgarpour B, Akhondzadeh S
J Psychopharmacol
. 2020 Mar;
34(5):506-513.
PMID: 32122230
Introduction And Objectives: Vortioxetine, a novel antidepressant, may be an interesting candidate for adjunctive therapy of schizophrenia. Our primary objective was to investigate the effect of vortioxetine on negative symptoms,...